corcept8k.htm
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Form
8-K
Current Report
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of
Report (Date of
earliest event reported): August 11,
2009
Corcept
Therapeutics Incorporated
(Exact
name of registrant as specified in its charter)
000-50679
(Commission File
Number)
|
Delaware
|
|
77-0487658
|
|
(State or
other jurisdiction of
|
|
(I.R.S.
Employer Identification No.)
|
|
incorporation)
|
|
|
149
Commonwealth Drive
Menlo
Park, CA 94025
(Address
of principal executive offices, with zip code)
(650)
327-3270
(Registrant's
telephone number, including area code)
(Former
name or former address, if changed since last report)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General
Instruction A.2. below):
|
o
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
|
|
o
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
|
o
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
|
|
o
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
Item
2.02 Results of Operations and Financial Condition
On August
11, 2009 the Company issued a press release announcing its financial results for
the quarter ended June 30, 2009. The press release is attached hereto
as Exhibit 99.1 and incorporated by reference.
This
information and the information contained in the press release attached as
Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of the
Exchange Act of 1934, as amended, or otherwise subject to the liabilities of
that Section. This information and the information contained in the press
release attached as Exhibit 99.1 is not incorporated by reference into any
filings of Corcept Therapeutics Incorporated made under the Securities Act of
1933, as amended, whether made before or after the date of the Current Report,
regardless of any general incorporation language in the filing unless
specifically stated so therein.
Item
7.01 Regulation FD Disclosure
On August
11, 2009 the Company issued a press release announcing its financial results for
the quarter ended June 30, 2009. The press release is attached hereto
as Exhibit 99.1 and incorporated by reference.
This
information and the information contained in the press release attached as
Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of the
Exchange Act of 1934, as amended, or otherwise subject to the liabilities of
that Section. This information and the information contained in the press
release attached as Exhibit 99.1 is not incorporated by reference into any
filings of Corcept Therapeutics Incorporated made under the Securities Act of
1933, as amended, whether made before or after the date of the Current Report,
regardless of any general incorporation language in the filing unless
specifically stated so therein.
Item
9.01 Financial Statements and Exhibits
(a)
Financial statements:
None
(b)
Pro forma financial information:
None
(c)
Shell company transactions:
None
(d)
Exhibits
99.1
Press Release of Corcept Therapeutics Incorporated
dated August 11, 2009.
SIGNATURES
Pursuant to the requirements of the
Securities Exchange Act of 1934, the Registrant has duly caused this report to
be signed on its behalf by the undersigned hereunto duly
authorized.
CORCEPT THERAPEUTICS
INCORPORATED
| Date: August
12, 2009 |
By:
/s/ Caroline
M. Loewy |
| |
Caroline
M. Loewy |
| |
Chief Financial Officer |